Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Acquisition (Tables)

Acquisition (Tables)

9 Months Ended

Aug. 31, 2018

The following summarizes the fair value of the consideration of the Acquisition:


Consideration
Cash	$	10,500,000
Cryo-Cell common stock		3,500,000
Cord blood inventory earnout		4,698,255

Consideration	$	18,698,255

Summary of Preliminary Allocation of Total Purchase Price

The following summarizes the preliminary allocation of the total purchase price for the Acquisition:


Accounts receivable	$	121,454
Inventory		16,037,957
Prepaid expenses		68,867
Property and equipment		568,407
Other asset—Tiahne capital stock		308,000
Brand		31,000
Customer relationships		960,000

Total identifiable net assets acquired		18,095,685

Less: Deferred revenue		(1,405,406	)

Goodwill		2,007,976

Total	$	18,698,255

Schedule of Unaudited Pro Forma Results

The following table provides the Company’s consolidated unaudited pro forma revenues, net income per basic and diluted common share had the results of the acquired businesses’ operations been included in its operations commencing on December 1, 2016, based on available information related to the respective operations. This proforma information is presented is not necessarily indicative either of the combined results of operations that actually would have been realized by the Company had the acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results and does not account for any operation improvements to be made by the Company post-acquisition.


	Three months ended August 31,					Nine months ended August 31,
	2018		2017			2018			2017
Revenue	$	7,871,222	$	8,212,179		$	22,794,591		$	22,858,031
Net income (loss)	$	244,984	($	83,925	)	($	3,797,189	)	($	594,359	)
Earnings (loss) per share:
Basic	$	0.03	($	0.01	)	($	0.52	)	($	0.08	)
Diluted	$	0.03	($	0.01	)	($	0.52	)	($	0.08	)